IPM researchers publish scientific and technical articles on a variety of topics from product development and clinical trial results to regulatory policy. Scroll through or use the Filtered Search in the left sidebar to locate articles by keyword, author, journal name or year published.
Development of a Combination Microbicide Gel Formulation Containing IQP-0528 and Tenofovir for the Prevention of HIV Infection
Ham AS, Ugaonkar SR, Shi L, Buckheit KW, Lakougna H, Nagaraja U, Gwozdz G, Goldman L, Kiser PF, Buckheit RW Jr. Journal of Pharmaceutical Sciences. 101, no. 4 (April 2012):1423-35. Epub 6 Jan 2012.
Pharmacokinetics of Tenofovir following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques.
Nuttall J, Kashuba A, Wang R, White N, Allen P, Robert J, Romano J. Antimicrobial Agents and Chemotherapy. 56, no. 1 (January 2012):103-9. Epub 10 October 2011.
Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles.
das Neves J, Sarmento B, Amiji MM, Bahia MF. Journal of Pharmaceutical and Biomedical Analysis. 52, no. 2 (5 June 2010):167-72. Epub 2010 Jan 15.
Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: optimization by an artificial neural network.
Woolfson A.D., Umrethia M.L., Kett V.L., Malcolm R.K. International Journal of Pharmaceutics 388, no.1-2 (2010):136-143.
Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir.
Johnson T.J., Gupta K.M., Fabian J., Albrights T.H., Kiser P.F. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 39, no. 4 (2010):...
Inhibition of HIV-1 infection by the candidate microbicide, dapivirine, a nonnucleoside reverse transcriptase inhibitor.
Fletcher P., Harman S., Azijn H., Armanasco N., Manlow P., Perumal D., de Bethune M-P., Nuttall J., Romano J., Shattock R. Antimicrobial Agents and Chemotherapy 53, no. 2 (2009):487-95.
Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C] dapivirine for 7 days.
Nuttall J.P., Thake D.C., Lewis M.G., Ferkany J.W., Romano J.W., Mitchnick M.A. Antimicrobial Agents and Chemotherapy 52, no. 3(2008) :909-14.
Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development.
Colleluori D.M., Tien D., Kang F., Pagliei T., Kuss R., McCormick T., Watson K., McFadden K., Chaiken I., Buckheit R.W., Jr, Romano J.W. Protein Expression and Purification 39, no. 2 (2005): 229-36.
Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States
van der Straten A, Panther L, Laborde N, Hoesley CL, Cheng H, Husnik MJ, Horn S, Nel A, Soto-Torres L, Chen BA. AIDS and Behavior. 20, no. 11 (November 2016): 2644-2653.
Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial
Dezzutti CS, Richardson-Harman N, Rohan L, Marzinke MA, Hoesley CJ, Panther L, Johnson S, Nuttall JP, Nel A, Chen BA. Medicine 95, no. 8 (2016 Jul): e4174. doi: 10.1097/MD.0000000000004174.